INmune Bio Inc.

https://www.inmunebio.com

INmune Bio Inc. is a clinical-stage biotechnology company dedicated to developing novel immunotherapies that reprogram the innate immune system to combat debilitating diseases such as cancer and Alzheimer's disease. The company's core mission is centered on a patient-centric, pioneering scientific approach to address unmet medical needs by modulating the body's natural defense mechanisms. Headquartered in Boca Raton, Florida, INmune Bio was incorporated in 2015.

INmune Bio's pipeline is built upon three distinct product platforms: CORDStrom, XPro (DN-TNF), and INKmune. The CORDStrom platform utilizes proprietary human umbilical cord-derived mesenchymal stromal/stem cells (hucMSCs) and recently completed a blinded randomized trial for recessive dystrophic epidermolysis bullosa. The XPro platform, featuring XPro1595 (also known as pegipanermin or INB03), is a Dominant-Negative Tumor Necrosis Factor (DN-TNF) product designed to selectively neutralize soluble TNF, a key driver of inflammation and immune dysfunction, with a primary focus on neuroinflammation in Alzheimer's disease. The INKmune platform is a cell-based medicine engineered to prime a patient's natural killer (NK) cells to eliminate minimal residual disease in various cancers, currently undergoing trials for metastatic castration-resistant prostate cancer.

In recent developments, David J. Moss was appointed CEO in August 2025, succeeding co-founder RJ Tesi, signaling a strategic refocusing on core therapeutic areas. The company has achieved FDA alignment on an integrated Phase 2b/3 registrational pathway for XPro1595 in early Alzheimer's disease, utilizing a biomarker-enriched design to target patients with neuroinflammation. Additionally, preclinical data for INB03 (XPro1595) has shown promise in overcoming resistance and reducing metastases in HER2-positive breast cancer models, and regulatory filings for CORDStrom are anticipated by mid-2026. As a publicly traded entity on the NASDAQ Capital Market under the ticker INMB, INmune Bio's operational model is heavily centered on research and development and clinical trial progression.

Latest updates

INmune Bio Data Shows Resistance-Breaking Potential in HER2+ Breast Cancer

Event summary

  • INmune Bio presented preclinical data at AACR 2026 demonstrating INB03 (XPro1595) enhances the efficacy of tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer models.
  • The data indicates INB03 overcomes resistance to TKIs like lapatinib and tucatinib, significantly reducing cell proliferation and metastatic spread.
  • The mechanism involves INB03 down-regulating MUC4, a protein that shields HER2 and prevents therapies from binding effectively.
  • The research was conducted in collaboration with the Instituto de Biología y Medicina Experimental (IBYME-CONICET) in Buenos Aires, Argentina.

The big picture

The ongoing challenge of drug resistance in HER2-positive breast cancer represents a significant clinical and commercial hurdle. INmune Bio’s data suggests a novel approach to circumventing this resistance by targeting the TNF pathway, potentially broadening the applicability of existing HER2-targeted therapies. The company's broader platform strategy, encompassing CORDStrom™, XPro™, and INKmune®, introduces complexity but also diversification of risk.

What we're watching

Clinical Translation
The preclinical efficacy observed will need to be replicated in human clinical trials to validate INB03’s potential as a combination therapy.
Regulatory Pathway
Given the complexity of combination therapies, the regulatory pathway for INB03 will likely be more challenging than for single-agent drugs, potentially impacting timelines.
Commercial Adoption
The success of INB03 will depend on its ability to address a significant unmet need in a market already crowded with HER2-targeted therapies, requiring a clear value proposition for physicians and patients.

INmune Bio Advances Clinical Pipeline, Burns Through Cash Reserves

Event summary

  • INmune Bio reported a net loss of $45.9 million for 2025, compared to $42.1 million the prior year.
  • The company estimates its cash runway extends to Q1 2027, with approximately $24.8 million in cash and equivalents as of December 31, 2025.
  • INmune Bio sold 4.3 million shares in 2025, generating $27.5 million in net proceeds.
  • The CORDStrom™ program is on track for UK MAA submission mid-summer, followed by EMA and FDA filings.
  • XPro™ has achieved alignment on an adaptive Phase 2b/3 registrational pathway with the FDA.

The big picture

INmune Bio's transition to a late-stage clinical company is predicated on the successful advancement of CORDStrom™ and XPro™. While the company has made progress in de-risking its pipeline, the limited cash runway and the inherent uncertainties of clinical development and regulatory approval present significant challenges. The company's ability to secure additional funding and execute its clinical programs efficiently will be crucial for long-term success.

What we're watching

Capital Needs
The company's Q1 2027 cash runway highlights the ongoing need for capital, potentially necessitating further equity or debt financing to support late-stage clinical trials and eventual commercialization.
Regulatory Risk
The success of CORDStrom™ hinges on timely regulatory approvals in the UK, EU, and US; any delays or rejections could significantly impact the company's valuation and future prospects.
Clinical Execution
The adaptive Phase 2b/3 trial design for XPro™ introduces complexity and risk; the go/no-go decision at the Phase 2b stage will be critical in determining the viability of the program.

INmune Bio's Alzheimer's Trial Data Validates Biomarker-Enriched Approach

Event summary

  • INmune Bio's Phase 2 MINDFuL trial data, featuring prominently at AD/PD 2026, demonstrated efficacy in a patient subgroup enriched for inflammatory biomarkers.
  • Malú Gámez Tansey, a leading neuroimmunologist, highlighted the trial's success as a blueprint for Alzheimer's drug development.
  • The trial focused on XPro™ (pegipanermin), a TNF inhibitor, and showed consistent positive results across nearly all efficacy endpoints in the targeted patient group.
  • Following a positive End-of-Phase 2 meeting with the FDA, INmune Bio is advancing to an integrated Phase 2b/3 registrational program.
  • The company's stock ticker is INMB on NASDAQ.

The big picture

The MINDFuL trial's success underscores a growing trend in Alzheimer's drug development: moving beyond broad-spectrum approaches to precision medicine targeting specific patient subgroups. This biomarker-driven strategy represents a significant departure from traditional clinical trial design and could reshape the development pathway for neurodegenerative diseases, but also introduces new complexities in patient identification and trial execution. The validation of this approach by a respected figure like Dr. Tansey lends significant credibility to INmune Bio's strategy and could influence future investment decisions in the field.

What we're watching

Clinical Execution
The success of the Phase 2b/3 trial hinges on replicating the biomarker enrichment strategy's effectiveness in a larger patient population, potentially exposing vulnerabilities in patient selection criteria.
Regulatory Risk
While the FDA alignment is positive, the agency's acceptance of the biomarker-driven approach could be contingent on continued validation of the predictive power of those biomarkers in the Phase 2b/3 study.
Competitive Landscape
Other companies pursuing Alzheimer's therapies targeting inflammation will be closely observing INmune Bio's progress, and any setbacks could accelerate a shift towards alternative therapeutic strategies.

INmune Bio Advances Alzheimer's Candidate with FDA Alignment

Event summary

  • INmune Bio received FDA alignment to advance XPro1595 into a registrational study for early Alzheimer’s disease, following completion of the Phase 2 MINDFuL trial.
  • The registrational study will target patients with Alzheimer's Disease and biomarkers of Inflammation.
  • A webinar on February 27, 2026, will detail the study design and rationale, featuring clinical experts Dr. Michael Woodward and Dr. Sharon Cohen.
  • INmune Bio is exploring global partnerships to accelerate XPro1595’s development and commercialization.

The big picture

Alzheimer’s disease drug development remains a high-failure, high-reward area, with recent successes like lecanemab demonstrating the potential for disease-modifying therapies. INmune Bio’s focus on neuroinflammation represents a distinct therapeutic approach, but the registrational trial will be a crucial test of its efficacy and the validity of its biomarker strategy. Securing a global partner will be key to navigating the complex regulatory and commercial landscape associated with a novel Alzheimer’s treatment.

What we're watching

Regulatory Risk
While the FDA alignment is positive, the registrational study’s success remains contingent on meeting endpoints and navigating potential future regulatory hurdles.
Partner Dynamics
The stated pursuit of a global partnership suggests INmune Bio recognizes limitations in its own commercialization capabilities, and the terms of any such deal will be critical to value.
Biomarker Validation
The enrichment strategy relying on biomarkers will require ongoing validation to ensure patient selection accurately predicts treatment response and supports regulatory approval.

INmune Bio to Present RDEB Trial Data, Spotlighting Systemic Approach

Event summary

  • INmune Bio will host a webinar on February 26, 2026, to present data from the MissionEB Phase III clinical trial for CORDStrom in recessive dystrophic epidermolysis bullosa (RDEB).
  • The trial data will focus on systemic disease-modifying capabilities, specifically examining EBDASI scores, nutritional status, symptom reduction, and quality of life improvements.
  • Dr. Anna Martinez, principal investigator of the MissionEB trial, and Professor Mark Lowdell, Chief Scientific Officer of INmune Bio, will present the findings.
  • CORDStrom is a cell medicine comprised of pooled, allogeneic human umbilical cord-derived mesenchymal stromal cells (hucMSCs) designed as a systemic therapy, contrasting with current topical treatments.

The big picture

INmune Bio’s CORDStrom represents a shift towards systemic therapies for RDEB, a debilitating rare disease with limited treatment options. The Phase III data presentation is a pivotal moment for the company, as it seeks to validate its platform and potentially disrupt the current standard of care focused on topical wound management. Success hinges on demonstrating meaningful clinical improvements and navigating the complexities of manufacturing and regulatory approval for cell-based therapies.

What we're watching

Clinical Efficacy
The webinar’s data on EBDASI scores and symptom reduction will be critical in assessing CORDStrom’s true clinical impact, as these metrics are key drivers of regulatory approval and market adoption.
Manufacturing Scalability
Given CORDStrom’s reliance on pooled hucMSCs, the ability to consistently produce sufficient quantities of high-quality material for commercialization will be a significant operational hurdle to monitor.
Market Adoption
The success of CORDStrom will depend on physician and patient acceptance of a systemic approach to RDEB, which may require a shift in treatment paradigms and reimbursement models.

FDA Alignment Paves Registration Pathway for INmune Bio's Alzheimer's Candidate

Event summary

  • INmune Bio received formal FDA minutes confirming alignment on a Phase 2b/3 clinical development strategy for XPro1595 in early Alzheimer’s Disease.
  • The FDA supports INmune Bio’s enrichment-led trial design, targeting patients with specific inflammatory biomarker profiles.
  • CDR-SB will serve as the sole primary efficacy endpoint for the Phase 3 trial, aligning with industry standards.
  • The Phase 2b portion will enroll ~300 participants over 9 months, followed by a Phase 3 enrollment of ~1,000 participants over 18 months.
  • An exploratory cohort of ~20% of patients will be included to assess broader effects of XPro1595.

The big picture

The FDA’s support for INmune Bio’s precision medicine approach reflects a growing trend towards targeted therapies in Alzheimer’s disease, moving away from broad-spectrum treatments. This validation is critical for INmune Bio, which has been developing XPro1595 as a differentiated treatment based on immune modulation. The reliance on CDR-SB as the primary endpoint also underscores the pressure on Alzheimer’s therapies to demonstrate meaningful clinical benefit, given the recent regulatory scrutiny of therapies with questionable efficacy.

What we're watching

Execution Risk
The success of the integrated Phase 2b/3 trial hinges on effectively identifying and enrolling the enriched patient population, which could be challenging given the reliance on multiple biomarkers.
Regulatory Headwinds
While the FDA has indicated alignment, the agency's feedback isn't a guarantee of approval, and future interactions could reveal unexpected hurdles or require protocol modifications.
Commercial Viability
The inclusion of an exploratory cohort suggests uncertainty about XPro1595's efficacy in a broader patient population, potentially impacting its commercial appeal if the enriched cohort proves essential for success.

INmune Advances RDEB Therapy Toward UK Approval, Eyes Pediatric Incentive

Event summary

  • INmune Bio submitted a pre-submission package for CORDStrom™ to the UK MHRA for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
  • The pre-submission process aims to streamline the full Marketing Authorization Application (MAA) and accelerate potential approval.
  • Commercial-scale manufacturing runs at the CGT Catapult facility have confirmed product readiness.
  • INmune anticipates filing a full MAA in mid-summer 2026, followed by US submissions in Q4 2026.
  • The reauthorization of the FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program through 2029 could provide a significant incentive for US approval.

The big picture

The advancement of CORDStrom™ represents a significant opportunity to address a severe unmet medical need in RDEB, a debilitating condition affecting approximately 1 in 1 million births. The pre-submission strategy highlights a growing trend among biopharma companies to engage with regulators early in the approval process. The reauthorized PRV program underscores the government’s commitment to incentivizing therapies for rare pediatric diseases, potentially accelerating commercialization and boosting investor returns.

What we're watching

Regulatory Response
The MHRA’s feedback on the pre-submission package will be critical in shaping the timeline and potential requirements for full approval, and will reveal the agency’s appetite for novel cell therapies in rare diseases.
Manufacturing Scale
While initial manufacturing runs have been successful, sustained, large-scale production of CORDStrom™ will be essential to meet potential demand and avoid supply chain bottlenecks post-approval.
PRV Utilization
INmune’s ability to secure and utilize the Rare Pediatric Disease Priority Review Voucher will significantly impact the speed of US approval and the company’s overall valuation.

INmune Bio Shows Alzheimer's Signal in Subgroup, Advances RDEB Therapy

Event summary

  • INmune Bio reported clinical learnings from its Phase 2 Alzheimer’s disease trial (MINDFuL), showing a treatment effect in a predefined subgroup of amyloid-positive patients with neuroinflammation.
  • The company is advancing CORDStrom™ for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with pilot-scale manufacturing runs completed and plans for a Marketing Authorization Application (MAA) submission to the UK’s MHRA in mid-summer 2026.
  • As of September 30, 2025, INmune Bio held approximately $27.7 million in cash and cash equivalents, sufficient to fund operations through year-end 2026.
  • A peer-reviewed study published in December 2025 highlighted the therapeutic potential of CORDStrom™.

The big picture

INmune Bio's strategy of targeting neuroinflammation in Alzheimer's disease represents a shift towards precision medicine approaches, aligning with evolving regulatory expectations and payer demands. The company's focus on rare diseases like RDEB, while niche, offers a potential pathway to accelerated approval and market exclusivity. The observed signal in the MINDFuL trial, while limited to a subgroup, provides a potential foothold in a market dominated by larger competitors like Biogen.

What we're watching

Regulatory Risk
The success of CORDStrom™ hinges on timely regulatory approvals from the MHRA and FDA, and any delays in the MAA or BLA submissions could significantly impact the company's timeline and valuation.
Clinical Validation
Whether INmune Bio can replicate the observed Alzheimer’s signal in a larger, registration-quality trial will be critical to validating the XPro™ program and attracting further investment.
Manufacturing Scale
The ability to consistently manufacture CORDStrom™ at commercial scale, as demonstrated by the CGT Catapult pilot runs, will be essential for meeting potential demand and achieving regulatory approval.

INmune Bio Study Bolsters Stromal Cell Therapy Platform, Eyes 2026 BLA

Event summary

  • INmune Bio published a peer-reviewed article in Cytotherapy highlighting the potential of mesenchymal stromal cell (MSC) therapies, specifically its CORDStrom™ platform.
  • The article, co-authored by INmune Bio’s Dr. Nikita M. Patel, reviews current knowledge and identifies gaps in MSC therapy development.
  • CORDStrom™ is currently being developed for recessive dystrophic epidermolysis bullosa (RDEB), with a Biologics License Application (BLA) and Marketing Authorization Application (MAA) expected in 2026.
  • The CORDStrom™ platform utilizes a depot-delivery method and aims to create off-the-shelf, allogeneic, pooled hucMSCs.

The big picture

The MSC therapy field is gaining traction as a potential treatment for a range of inflammatory and autoimmune conditions, but faces challenges in standardization and efficacy. INmune Bio’s CORDStrom™ platform aims to address these challenges with its off-the-shelf, allogeneic approach. This publication underscores the company’s commitment to scientific rigor and positions CORDStrom™ as a potentially significant player in the evolving cell therapy landscape, though regulatory and clinical trial success remain critical.

What we're watching

Regulatory Approval
The success of the planned BLA and MAA filings in 2026 for RDEB will be a key indicator of CORDStrom™’s commercial viability and the platform’s broader potential.
Platform Expansion
How effectively INmune Bio can leverage the CORDStrom™ platform to develop indication-specific products beyond RDEB will determine its long-term revenue diversification.
Scientific Validation
The pace at which subsequent research builds upon the insights from this Cytotherapy publication will influence investor confidence and potential partnerships.
CID: 529